596 related articles for article (PubMed ID: 28356053)
21. Comparison of the effectiveness of topiramate and sodium valproate in pediatric migraine.
Unalp A; Uran N; Oztürk A
J Child Neurol; 2008 Dec; 23(12):1377-81. PubMed ID: 19073842
[TBL] [Abstract][Full Text] [Related]
22. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Melatonin on Reducing the Frequency and Severity of Migraine Attacks: A Double-Blind, Randomized Clinical Trial.
Mehramiri A; Shalilahmadi D; Mohamadianinejad SE; Kouti L; Hosseinpour Y
Iran J Med Sci; 2024 May; 49(5):313-321. PubMed ID: 38751874
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of topiramate and valproate in chronic migraine.
Bartolini M; Silvestrini M; Taffi R; Lanciotti C; Luconi R; Capecci M; Provinciali L
Clin Neuropharmacol; 2005; 28(6):277-9. PubMed ID: 16340383
[TBL] [Abstract][Full Text] [Related]
25. Sodium valproate prophylaxis in childhood migraine.
Serdaroglu G; Erhan E; Tekgul H; Oksel F; Erermis S; Uyar M; Tutuncuoglu S
Headache; 2002 Sep; 42(8):819-22. PubMed ID: 12390647
[TBL] [Abstract][Full Text] [Related]
26. Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department: A randomized clinical trial.
Dogruyol S; Gur STA; Akbas I; Kocak MB; Kocak AO; Ceylan M; Tekyol D
Am J Emerg Med; 2022 May; 55():126-132. PubMed ID: 35313227
[TBL] [Abstract][Full Text] [Related]
27. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience.
Stillman MJ; Zajac D; Rybicki LA
Headache; 2004 Jan; 44(1):65-9. PubMed ID: 14979885
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine.
Cady RK; Saper J; Dexter K; Cady RJ; Manley HR
Headache; 2015 Apr; 55(4):529-42. PubMed ID: 25828648
[TBL] [Abstract][Full Text] [Related]
29. Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam--Pilot study.
Mundlamuri RC; Sinha S; Subbakrishna DK; Prathyusha PV; Nagappa M; Bindu PS; Taly AB; Umamaheswara Rao GS; Satishchandra P
Epilepsy Res; 2015 Aug; 114():52-8. PubMed ID: 26088885
[TBL] [Abstract][Full Text] [Related]
30. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects.
Young W; Shaw J; Bloom M; Gebeline-Myers C
Headache; 2008; 48(10):1490-8. PubMed ID: 19076647
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Levetiracetam and sodium Valproate in migraine prophylaxis: A randomized placebo-controlled study.
Sadeghian H; Motiei-Langroudi R
Ann Indian Acad Neurol; 2015; 18(1):45-8. PubMed ID: 25745310
[TBL] [Abstract][Full Text] [Related]
32. Retrospective Chart Review of Intravenous Valproate Sodium as a Preventive Treatment for Patients With Chronic Migraine.
Riggins N; Ehrlich A; Sawhney H; Dapkus L; Levin M
Headache; 2020 Mar; 60(3):617-620. PubMed ID: 31985052
[TBL] [Abstract][Full Text] [Related]
33. Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
Suzuki K; Iizuka T; Sakai F
Intern Med; 2007; 46(13):959-63. PubMed ID: 17603233
[TBL] [Abstract][Full Text] [Related]
34. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study.
Jensen R; Brinck T; Olesen J
Neurology; 1994 Apr; 44(4):647-51. PubMed ID: 8164818
[TBL] [Abstract][Full Text] [Related]
35. Comparing Prophylactic Effect of Levetiracetam, Sodium Valproate, and Propranolol in Pediatric Migraine: A Randomized Clinical Trial.
Fayyazi A; Pezeshki N; Mansuri H; Khajeh A
Iran J Child Neurol; 2023; 17(4):105-115. PubMed ID: 38074934
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of levetiracetam for migraine prophylaxis: A systematic review.
Watkins AK; Gee ME; Brown JN
J Clin Pharm Ther; 2018 Aug; 43(4):467-475. PubMed ID: 29781197
[TBL] [Abstract][Full Text] [Related]
37. Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab.
Blumenfeld A; Ettrup A; Hirman J; Ebert B; Cady R
BMC Neurol; 2022 Jul; 22(1):251. PubMed ID: 35804294
[TBL] [Abstract][Full Text] [Related]
38. Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT]).
Beran RG; Spira PJ
Cephalalgia; 2011 Apr; 31(5):530-6. PubMed ID: 21059626
[TBL] [Abstract][Full Text] [Related]
39. Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in northern India.
Verma A; Srivastava D; Kumar A; Singh V
Clin Neuropharmacol; 2013; 36(6):193-7. PubMed ID: 24201237
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine.
Waberzinek G; Marková J; Mastík J
Neuro Endocrinol Lett; 2007 Feb; 28(1):59-64. PubMed ID: 17277725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
